CD4 and colitis: The following experimental groups were included in the final therapeutic comparison: Normal (PBMC-humanized mice without DSS-induced colitis), Vehicle (PBMC-humanized mice with DSS-induced colitis, and treated with PBS), Ozanimod (PBMC-humanized mice with DSS-induced colitis and treated with 5 mg/kg Ozanimod), Autologous Treg (PBMC-humanized mice with DSS-induced colitis and treated with 5 × 106 expanded autologous Treg cells), and Non-Treg (PBMC-humanized mice with DSS-induced colitis and treated with 5 × 106 autologous CD4+CD25− effector T cells).